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Abstract
Alzheimer disease (AD) is recognized as the six leading 
cause of the death in the United States. As of now, there is 
no cure for this fatal disease. The current treatment methods 
can only temporarily slow the worsening of symptoms. 
Research data suggested that an excess generation of 
hydroxyl radical in the brain causing the aggregation 
of Amyloid-β (Aβ) peptide which is considered to be 
responsible for Alzheimer's disease. Thus, there is a pressing 
need to find a suitable drug which can quench hydroxyl 
radicals effectively and stop or slow down the formation of 
aggregation of Aβ peptide. The primary objective of the 
project is to find out a dual functional drug which can quench 
the reactive hydroxyl radicals produced in the brain and 
prevent Aβ peptide chains to come close to form Aβ peptide 
aggregate at the same time. A small organic molecule 1,5-
dihydroxynapthalene (DHN) was found to quench hydroxyl 
radical at a rate of 3 X 10-4 s-1.  An independent experiment 
suggested that it intercalated efficiently into the Aβ peptide 
chains. Upon addition of meso-tetra(N-methyl-4-
pyridyl)porphyrin tetrachloride (TMPyP) with DHN, a strong 
synergistic effect in quenching the hydroxyl radical and 
intercalating into the Aβ peptide chains was observed. This 
data suggests that DHN or DHN & TMPyP are the potential 
drug for Alzheimer disease treatment. 
Methods
1. Quenching of hydroxyl radical generated in situ via
Fenton reaction where DHN and methylene blue are used
as hydroxyl radical quenchers.
2. Optimization of [DHN] concentration for hydroxyl radical
quenching reactions.
3. DHN, TMPyP, and Juglone effect on Amyloid-β
aggregation
4. Study hydroxyl radical effects on Amyloid-β aggregation
using TMPyP, DHN, and Fenton reagents.
Results
3. DHN, TMPyP, and Juglone effect on Amyloid-β
aggregation observed by UV-Vis spectroscopy
Figure 2: Absorption spectra of DHN (301 nm) in the 
presence of amyloid-β. (a) 1 x 10-5 M DHN and (b) DHN 
with 8 μM amyloid-β over time. Spectra was recorded every 
10 minutes for an hour.
Figure 3: Absorption spectra of TMPyP (423 nm) in the 
presence of amyloid-β. Spectra was recorded every 10 
minutes for an hour. (a) 8 μM amyloid-β (b) 6 μM TMPyP (c) 
TMPyP and Aβ at 0 mins (d) TMPyP and Aβ at 60 mins. 
Figure 4: Absorption spectra of Juglone (429 nm) in the 
presence of amyloid-β. (a) 5 x 10-5 M Juglone and (b) Juglone
with 8 μM amyloid-β over time. Spectra was recorded every 
10 minutes for an hour. 
4. Hydroxy radical effects on Amyloid-β aggregation
observed using UV-visible spectroscopy and TMPyP
Conclusion
• The oxidation of methylene blue (3.1 x 10-3 s-1) was
drastically reduced in the presence of DHN (3.0 x 10-4 s-1).
These results suggest that DHN could be a possible option
for slowing the rate of amyloid-β aggregation.
• The absorption spectra revealed that DHN successfully
intercalated into the peptide chains and can prevent or slow
down amyloid-β aggregate formation. Synergistic effect
observed upon addition of TMPyP with DHN.
• Figure 5 shows a relatively slow decrease and right shift in
the TMPyP peak at 423 nm. This is indicative of a TMPyP
and Aβ aggregation interaction. However, in the presence
of DHN, the absorption spectra of TMPyP decreases
indicating TMPyP is selectively reacting with hydroxyl
radicals. Further investigation is need to understand what is
occurring during the reaction.
Introduction
Approximately, 200,000 Americans under the age of 65 are 
suffering from Alzheimer disease today and, unfortunately, 
there is currently no cure. Researchers believe that the cause 
of Alzheimer's disease is mostly due to the aggregation of 
Amyloid-β (Aβ) peptide.1 Generally, the aggregation of Aβ 
is initiated and enhanced when the balance between oxidants 
and antioxidants is disrupted in the brain.2 This unbalancing 
process between antioxidant and oxidant is called oxidative 
stress. Oxidative stress can occur when there is an increase in 
free radical concentrations within the brain. Research studies 
indicated that the major source of free radicals in our brain is 
due to the reduction of molecular oxygen in water.  It has 
been proven that oxygen gas is reduced into superoxide 
radical, which further reduced into hydrogen peroxide.  
Hydrogen peroxide is then subsequently reduced into a 
highly reactive hydroxyl radicals,2 this reactive oxygen 
species (ROS) can disrupt lipids membranes, proteins, 
nucleic acids,3 via a chain of irreversible oxidative reactions.  
Thus, our interest is to develop drugs and/or methods for (1) 
quenching/trapping excess produced hydroxyl radicals into 
non-toxic products and (2) stopping or slowing down the 
formation of aggregation of amyloid β (Aβ) peptide. 
(Fenton Reaction) 
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Results
1. Quenching of hydroxyl radical generated in situ via Fenton
reaction where DHN and methylene blue (MB) are used as
hydroxyl radical quenchers.
Figure 1: A comparison of absorption spectra of methylene 
blue at 664 nm in the presence of (a) reactive oxygen species 
and (b) reactive oxygen species and DHN. 
2. Optimization of [DHN] for determining the slowest rate in































• Analyze atomic force microscopy imaging of Amyloid-β
aggregates in the presence of DHN.
• Assessment of conformational changed in the presence of
TMPyP and DHN by circular dichroism spectroscopy.
• Observer biomolecule interactions using surface plasmon
resonance.
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Results
Figure 5: Absorption spectra of DHN (301 nm) and TMPyP 
(423 nm) in the presence of amyloid-β and Fenton reaction. 
(a) 1.4 x 10-4 M DHN, 6 μM TMPyP and 8 μM amyloid-β (b)
DHN, TMPyP, Aβ and 3 mM Fe(II) (c) DHN, TMPyP, Aβ
with Fenton Reaction recorded over time. Spectra was
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